JP2023541771A5 - - Google Patents
Info
- Publication number
- JP2023541771A5 JP2023541771A5 JP2023504005A JP2023504005A JP2023541771A5 JP 2023541771 A5 JP2023541771 A5 JP 2023541771A5 JP 2023504005 A JP2023504005 A JP 2023504005A JP 2023504005 A JP2023504005 A JP 2023504005A JP 2023541771 A5 JP2023541771 A5 JP 2023541771A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- ligand
- protein according
- antigen
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054180P | 2020-07-20 | 2020-07-20 | |
| US63/054,180 | 2020-07-20 | ||
| US202163172626P | 2021-04-08 | 2021-04-08 | |
| US63/172,626 | 2021-04-08 | ||
| PCT/CA2021/051006 WO2022016270A1 (en) | 2020-07-20 | 2021-07-20 | Fusion proteins comprising a ligand-receptor pair and a biologically functional protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541771A JP2023541771A (ja) | 2023-10-04 |
| JP2023541771A5 true JP2023541771A5 (https=) | 2024-07-29 |
| JP7846668B2 JP7846668B2 (ja) | 2026-04-15 |
Family
ID=79729591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504005A Active JP7846668B2 (ja) | 2020-07-20 | 2021-07-20 | リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230331809A1 (https=) |
| EP (1) | EP4182357A4 (https=) |
| JP (1) | JP7846668B2 (https=) |
| KR (1) | KR20230042315A (https=) |
| CN (1) | CN116171167B (https=) |
| AU (1) | AU2021312554A1 (https=) |
| CA (1) | CA3145387A1 (https=) |
| MX (1) | MX2023000839A (https=) |
| WO (1) | WO2022016270A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7773991B2 (ja) * | 2020-03-23 | 2025-11-20 | ザイムワークス ビーシー インコーポレイテッド | マスクされたｉｌ１２融合タンパク質及びその使用方法 |
| IL314169A (en) * | 2022-01-26 | 2024-09-01 | Zymeworks Bc Inc | Trispecific immunomodulatory T cell engager proteins |
| US20240254223A1 (en) * | 2022-09-02 | 2024-08-01 | Novimmune Sa | Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof |
| CA3266966A1 (en) * | 2022-10-19 | 2024-04-25 | Zymeworks Bc Inc. | TRIVALENT AND TRISPECIFIC ANTIBODY CONSTRUCTIONS AND THEIR METHODS OF USE |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| US20250066478A1 (en) * | 2023-08-25 | 2025-02-27 | Ibio, Inc. | High-efficiency, conditionally-activated antibody discovery and masked antibodies |
| WO2025117851A1 (en) * | 2023-11-30 | 2025-06-05 | The General Hospital Corporation | Meso-fap with adam17 inhibitor or itk inhibitor |
| WO2025133042A2 (en) * | 2023-12-22 | 2025-06-26 | F. Hoffmann-La Roche Ag | Activatable fusion proteins and methods of use |
| WO2025170315A1 (ko) * | 2024-02-05 | 2025-08-14 | 주식회사 트리오어 | 이중 기능 도메인을 포함하는 융합단백질 및 이의 용도 |
| KR20250161096A (ko) * | 2024-05-07 | 2025-11-17 | 바이티디 주식회사 | Vista 및 msln에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| WO2025247847A1 (en) | 2024-05-30 | 2025-12-04 | Zytox Therapeutics Ab | A matriptase-cleavable substrate |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6509724B2 (ja) | 2012-04-20 | 2019-05-08 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| JP2017507900A (ja) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| JP7015244B2 (ja) | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| US11939385B2 (en) * | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
| WO2019080883A1 (en) | 2017-10-26 | 2019-05-02 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. | NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF |
| EP3897851A2 (en) * | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
-
2021
- 2021-07-20 WO PCT/CA2021/051006 patent/WO2022016270A1/en not_active Ceased
- 2021-07-20 CA CA3145387A patent/CA3145387A1/en active Pending
- 2021-07-20 CN CN202180051531.1A patent/CN116171167B/zh active Active
- 2021-07-20 JP JP2023504005A patent/JP7846668B2/ja active Active
- 2021-07-20 MX MX2023000839A patent/MX2023000839A/es unknown
- 2021-07-20 US US18/017,319 patent/US20230331809A1/en active Pending
- 2021-07-20 KR KR1020237005797A patent/KR20230042315A/ko active Pending
- 2021-07-20 EP EP21845766.1A patent/EP4182357A4/en active Pending
- 2021-07-20 AU AU2021312554A patent/AU2021312554A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541771A5 (https=) | ||
| JP7651450B2 (ja) | 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法 | |
| CN113840634B (zh) | 可活化蛋白质构建体及其用途 | |
| JP7591917B2 (ja) | Ｓｉｒｐ－アルファドメインまたはそのバリアントを有する構築物 | |
| US20240344046A1 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| Klaus et al. | pH-responsive antibodies for therapeutic applications | |
| US20250270314A1 (en) | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof | |
| JP2026040675A (ja) | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 | |
| JP7846668B2 (ja) | リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質 | |
| CN110719918B (zh) | 靶向至少cd3和hsa的异源二聚体多特异性抗体形式 | |
| EP4389226A2 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| Magdelaine-Beuzelin et al. | Structure–function relationships of the variable domains of monoclonal antibodies approved for cancer treatment | |
| WO2018097308A1 (ja) | リガンド結合活性が調整可能なリガンド結合分子 | |
| WO2019222282A1 (en) | Conditionally activated binding protein comprising a sterically occluded target binding domain | |
| CN115057936A (zh) | 异源二聚体多特异性抗体形式 | |
| US20210277054A1 (en) | Chromatography resin and uses thereof | |
| HK1217958A1 (zh) | 四价双特异性抗体 | |
| ES3056908T3 (en) | Adam9-binding molecules, and methods of use thereof | |
| US20230242676A1 (en) | Polypeptides, protein complexes and method for making same | |
| TW202402792A (zh) | 可調整配體結合活性的配體結合分子 | |
| US20220356457A1 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| CN117616049A (zh) | Fap/cd40结合分子及其医药用途 | |
| WO2024220397A1 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| CN119053622A (zh) | 一种抗ceacam5和ceacam6抗体及其应用 | |
| WO2025199124A1 (en) | Antibodies targeting cd318 (cdcp1) and uses thereof |